BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 11884480)

  • 1. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice.
    Brown GR; Lee E; Thiele DL
    J Immunol; 2002 Mar; 168(6):3065-71. PubMed ID: 11884480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF enhances CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease by IL-12-independent mechanisms.
    Brown GR; Lee EL; Thiele DL
    J Immunol; 2003 May; 170(10):5082-8. PubMed ID: 12734353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions.
    Brown GR; Thiele DL
    Eur J Immunol; 2000 Oct; 30(10):2900-7. PubMed ID: 11069072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor is critical for cytolytic T cell activity against allospecific hepatocytes and splenic targets in major histocompatibility complex class I disparate graft versus host disease.
    Ali S; Starwalt R; Kreck J; Whittington B; Brown GR
    J Interferon Cytokine Res; 2011 May; 31(5):423-31. PubMed ID: 21091241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease.
    Brown GR; Lee EL; El-Hayek J; Kintner K; Luck C
    J Immunol; 2005 Apr; 174(8):4688-95. PubMed ID: 15814693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A.
    Rolink AG; Pals ST; Gleichmann E
    J Exp Med; 1983 Feb; 157(2):755-71. PubMed ID: 6218218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection from T helper cell-mediated graft-versus-host disease by the presence of an MHC class I alloantigen is associated with perturbation of MHC class II-restricted responses by class I-derived peptides.
    Leibnitz RR; Lipsky PE; Thiele DL
    J Immunol; 1995 Aug; 155(4):1784-95. PubMed ID: 7636234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells.
    Thiele DL; Bryde SE; Lipsky PE
    J Immunol; 1988 Nov; 141(10):3377-82. PubMed ID: 3053897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of TNF in hepatic histopathological manifestations and hepatic CD8+ T cell alloresponses in murine MHC class I disparate GVHD.
    El-Hayek JM; Rogers TE; Brown GR
    J Leukoc Biol; 2005 Oct; 78(4):1001-7. PubMed ID: 16081594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparate role of LIGHT in organ-specific donor T cells activation and effector molecules in MHC class II disparate GVHD.
    Brown GR; Lane GW; Whittington BJ
    J Clin Immunol; 2010 Jan; 30(1):178-84. PubMed ID: 19826934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance induction of allo-class II H-2 antigen-reactive L3T4+ helper T cells and prolonged survival of the corresponding class II H-2-disparate skin graft.
    Hori S; Sato S; Kitagawa S; Azuma T; Kokudo S; Hamaoka T; Fujiwara H
    J Immunol; 1989 Sep; 143(5):1447-52. PubMed ID: 2527264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
    Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA
    J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated onset and increased severity of acute graft-versus-host disease following adoptive transfer of DR6-deficient T cells.
    Liu J; Heuer JG; Na S; Galbreath E; Zhang T; Yang DD; Glasebrook A; Song HY
    J Immunol; 2002 Oct; 169(7):3993-8. PubMed ID: 12244201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
    Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
    J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity.
    Hill GR; Teshima T; Rebel VI; Krijanovski OI; Cooke KR; Brinson YS; Ferrara JL
    J Immunol; 2000 Jan; 164(2):656-63. PubMed ID: 10623807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CD28 in acute graft-versus-host disease.
    Yu XZ; Martin PJ; Anasetti C
    Blood; 1998 Oct; 92(8):2963-70. PubMed ID: 9763584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-cell interaction in graft rejection responses: induction of anti-allo-class I H-2 tolerance is prevented by immune responses against allo-class II H-2 antigens coexpressed on tolerogen.
    Hori S; Kitagawa S; Iwata H; Ochiai T; Isono K; Hamaoka T; Fujiwara H
    J Exp Med; 1992 Jan; 175(1):99-109. PubMed ID: 1730930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC-II-independent CD4+ T cells induce colitis in immunodeficient RAG-/- hosts.
    Trobonjaca Z; Leithäuser F; Möller P; Bluethmann H; Koezuka Y; MacDonald HR; Reimann J
    J Immunol; 2001 Mar; 166(6):3804-12. PubMed ID: 11238623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CC chemokine receptor 2 expression in donor cells serves an essential role in graft-versus-host-disease.
    Rao AR; Quinones MP; Garavito E; Kalkonde Y; Jimenez F; Gibbons C; Perez J; Melby P; Kuziel W; Reddick RL; Ahuja SK; Ahuja SS
    J Immunol; 2003 Nov; 171(9):4875-85. PubMed ID: 14568968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD.
    Sprent J; Schaefer M; Korngold R
    J Immunol; 1990 Apr; 144(8):2946-54. PubMed ID: 1969878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.